137 related articles for article (PubMed ID: 27543619)
1. Presurgical Biomarker Performance in the Detection of Gleason Upgrading in Prostate Cancer.
Wittig K; Yamzon JL; Smith DD; Jeske DR; Smith SS
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1643-1645. PubMed ID: 27543619
[TBL] [Abstract][Full Text] [Related]
2. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
3. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
[TBL] [Abstract][Full Text] [Related]
4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
5. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
[TBL] [Abstract][Full Text] [Related]
6. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
8. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
9. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
12. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
[TBL] [Abstract][Full Text] [Related]
13. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
[TBL] [Abstract][Full Text] [Related]
14. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
15. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
[TBL] [Abstract][Full Text] [Related]
16. Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
Bokhorst LP; Roobol MJ; Bangma CH; van Leenders GJ
Prostate; 2017 Jul; 77(10):1137-1143. PubMed ID: 28543353
[TBL] [Abstract][Full Text] [Related]
17. The influence of PSA-RNA yield on the analysis of expressed prostatic secretions (EPS) for prostate cancer diagnosis.
Whelan C; Crocitto L; Kawachi M; Chan K; Smith D; Wilson T; Smith S
Can J Urol; 2013 Feb; 20(1):6597-602. PubMed ID: 23433128
[TBL] [Abstract][Full Text] [Related]
18. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]